Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Linda A. Kroger"'
Publikováno v:
Health physics. 115(5)
The field of medicine has been rapidly changing recently for providers and patients. This article considers how such changes have impacted the roles and responsibilities of the medical facility radiation safety officer. To supplement the personal exp
Autor:
Robert W. Derlet, Edwin M. Leidholdt, Cheryl E. Wraa, Linda A. Kroger, Jerrold T. Bushberg, Kenneth L. Miller, Marcia B. Hartman
Publikováno v:
The Journal of Emergency Medicine. 32:71-85
Recent world events have increased concern that hospitals must be prepared for radiological emergencies. Emergency departments (EDs) must be ready to treat patients suffering from injuries in combination with radiation exposure or contamination with
Neovascular Targeting with Cyclic RGD Peptide (cRGDf-ACHA) to Enhance Delivery of Radioimmunotherapy
Autor:
Kathleen R. Lamborn, Patricia A. Burke, Laird Miers, Sally J. DeNardo, Siegfried Matzku, Alfred Jonczyk, Linda A. Kroger, Gerald L. DeNardo, Simon L. Goodman, Bryan R. Leigh, Robert T. O'Donnell
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 15:71-79
Radioimmunotherapy (RIT) has been hampered by delivery of only a small fraction of the administered dose of radiolabeled MAb to tumor. A strategy for creating and controlling tumor vascular permeability would enable more effective RIT. The alpha v be
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 14:139-143
In order to improve radioimmunotherapy of lymphoma, a Lym-1 single-chain antigen-binding (scFv) protein molecule was produced. Because the commonly used polymerase chain reaction (PCR) method frequently causes unexpected mutations, we developed a non
Autor:
Sui Shen, Linda A. Kroger, Jerry P. Lewis, Gerald L. DeNardo, John P. McGahan, Qansy Salako, Sally J. DeNardo, Desiree S. Goldstein, Norman B. Levy, Kathleen R. Lamborn
Publikováno v:
Journal of Clinical Oncology. 16:3246-3256
PURPOSE Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes, has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with iodine 131 ((131)I). Based on the strategy of fractionating the total dose,
Autor:
Frederick J. Meyers, Robert T. O'Donnell, Gerald L. DeNardo, Sally J. DeNardo, Gary R. Mirick, Linda A. Kroger, Xu Bao Shi
Publikováno v:
The Prostate. 37:91-97
BACKGROUND Radioimmunotherapy (RIT) is a promising new modality for targeted, systemic delivery of radionuclides specifically to sites of androgen-independent metastatic prostate cancer. To be effective, RIT requires an antibody with specificity for
Autor:
R. H. Pak, David G. DeNardo, Claude F. Meares, J. K. Moran, X. Feng, Sally J. DeNardo, Gerald L. DeNardo, Linda A. Kroger
Publikováno v:
Hybridoma. 17:125-132
Monoclonal antibodies were raised against yttrium(III)-1, 4, 7, 10-tetraazacyclododecane-N,N',N''N'''--tetraacetic acid (Y-DOTA) and copper(II)-1, 4, 8, 11-tetraazacyclotetradecane-N,N',N'',N'''-tetraacetic acid (Cu-TETA). Four hybridomas with high Y
Autor:
Sui Shen, Sally J. DeNardo, Malcolm R. MacKenzie, Gary R. Mirick, Linda A. Kroger, Gerald L. DeNardo
Publikováno v:
Cancer Biotherapy and Radiopharmaceuticals. 13:1-12
A patient with aggressive, chemotherapy-resistant non-Hodgkins lymphoma (NHL) was treated with 131I-Lym-1, a mouse antibody, on a protocol designed for serial therapy. Human anti-mouse antibody (HAMA) developed within 1 month of initial therapy. The
Autor:
Gerald L. DeNardo, Linda A. Kroger, Sally J. DeNardo, Desiree S. Goldstein, Kathleen R. Lamborn
Publikováno v:
Cancer. 80:2706-2711
BACKGROUND Because most patients with advanced non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) respond to radioimmunotherapy (RIT), the study was designed to evaluate the relationship between response and survival in patients trea
Autor:
David L. Kukis, Sally J. DeNardo, Gerald L. DeNardo, Kathleen R. Lamborn, Robert T. O'Donnell, Linda A. Kroger, Carol M. Richman, A B S Laird Miers
Publikováno v:
Cancer. 80:2583-2590
BACKGROUND. The beneficial effects of radioimmunotherapy (RIT) may result from activation of molecular pathways that lead to programmed cell death (apoptosis). The influences of sequence and timing of 99 Y-DOTA-peptide-ChL6 antibody ( 90 Y-ChL6) and